Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Non-Current Assets: 2019-2025

Historic Other Non-Current Assets for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $25.5 million.

  • BridgeBio Pharma's Other Non-Current Assets rose 25.78% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 25.78%. This contributed to the annual value of $18.2 million for FY2024, which is 19.58% down from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Other Non-Current Assets is $25.5 million, which was up 40.97% from $18.1 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Other Non-Current Assets high stood at $49.8 million for Q2 2021, and its period low was $16.6 million during Q1 2025.
  • Moreover, its 3-year median value for Other Non-Current Assets was $20.3 million (2024), whereas its average is $20.1 million.
  • Per our database at Business Quant, BridgeBio Pharma's Other Non-Current Assets skyrocketed by 188.61% in 2021 and then tumbled by 41.21% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Other Non-Current Assets (Quarterly) stood at $33.0 million in 2021, then crashed by 38.77% to $20.2 million in 2022, then increased by 11.87% to $22.6 million in 2023, then declined by 19.58% to $18.2 million in 2024, then grew by 25.78% to $25.5 million in 2025.
  • Its Other Non-Current Assets stands at $25.5 million for Q3 2025, versus $18.1 million for Q2 2025 and $16.6 million for Q1 2025.